Metagenomi Therapeutics (MGX) Change in Accured Expenses (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Change in Accured Expenses for 4 consecutive years, with -$2.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 23.38% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$1.0 million (down 76.68% YoY), while the FY2025 annual figure was -$1.6 million, down 83.87% from the prior year.
• Change in Accured Expenses rose to -$2.0 million in Q1 2026 per MGX's latest filing, from -$3.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.0 million in Q3 2025 and bottomed at -$3.2 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged -$225769.2 across 4 years, with a median of -$318000.0 in 2024.
• On a YoY basis, Change in Accured Expenses climbed as much as 539.67% in 2025 and fell as far as 902.83% in 2025.
• Metagenomi Therapeutics' Change in Accured Expenses stood at $902000.0 in 2023, then slumped by 135.25% to -$318000.0 in 2024, then slumped by 902.83% to -$3.2 million in 2025, then jumped by 36.38% to -$2.0 million in 2026.
• Business Quant data shows MGX's Change in Accured Expenses at -$2.0 million in Q1 2026, -$3.2 million in Q4 2025, and $4.0 million in Q3 2025.